These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 11489802)
1. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Sadanaga N; Nagashima H; Mashino K; Tahara K; Yamaguchi H; Ohta M; Fujie T; Tanaka F; Inoue H; Takesako K; Akiyoshi T; Mori M Clin Cancer Res; 2001 Aug; 7(8):2277-84. PubMed ID: 11489802 [TBL] [Abstract][Full Text] [Related]
2. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. Tanaka F; Haraguchi N; Isikawa K; Inoue H; Mori M Oncol Rep; 2008 Nov; 20(5):1111-6. PubMed ID: 18949409 [TBL] [Abstract][Full Text] [Related]
3. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients. Hao X; Shao Y; Ren X; Liu H; Xu Q; Li H; Zhang P; An X; Ren B J Cancer Res Clin Oncol; 2002 Sep; 128(9):507-15. PubMed ID: 12242516 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829 [TBL] [Abstract][Full Text] [Related]
6. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643 [TBL] [Abstract][Full Text] [Related]
7. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806 [TBL] [Abstract][Full Text] [Related]
8. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides. Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158 [TBL] [Abstract][Full Text] [Related]
9. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Kono K; Takahashi A; Sugai H; Fujii H; Choudhury AR; Kiessling R; Matsumoto Y Clin Cancer Res; 2002 Nov; 8(11):3394-400. PubMed ID: 12429626 [TBL] [Abstract][Full Text] [Related]
11. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Connerotte T; Van Pel A; Godelaine D; Tartour E; Schuler-Thurner B; Lucas S; Thielemans K; Schuler G; Coulie PG Cancer Res; 2008 May; 68(10):3931-40. PubMed ID: 18483279 [TBL] [Abstract][Full Text] [Related]
12. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
13. [Inhibitory effect of dendritic cells pulsed with MAGE-3 peptide on transplanted murine gastric cancer in mice]. Lü B; Liu BY; Zhang Y; Chen XH; Zhu ZG; Yin HR; Lin YZ Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2120-3. PubMed ID: 16313822 [TBL] [Abstract][Full Text] [Related]
14. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient. Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215 [TBL] [Abstract][Full Text] [Related]
15. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471 [TBL] [Abstract][Full Text] [Related]
16. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912 [TBL] [Abstract][Full Text] [Related]
17. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide. Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730 [TBL] [Abstract][Full Text] [Related]
18. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414 [TBL] [Abstract][Full Text] [Related]
19. Vaccine Trials for the Clinician: Prospects for Tumor Antigens. Osanto S Oncologist; 1997; 2(5):284-299. PubMed ID: 10388061 [TBL] [Abstract][Full Text] [Related]
20. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]